Replication-dependent and -independent camptothecin cytotoxicity of seven human colon tumor cell lines

Oncology Research

Volumn 10, Issue 5, 1998, Pages 271-276

  Borovitskaya, Anna E ^a   D'Arpa, Peter ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

Camptothecin; Cytotoxicity; DNA replication; Topoisomerase I

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; ENZYME INHIBITOR;

ARTICLE; CELL CULTURE; CELL CYCLE S PHASE; DNA DAMAGE; DNA REPLICATION; DOSE RESPONSE; DRUG EFFECT; HUMAN;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; DNA DAMAGE; DNA REPLICATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; S PHASE; TUMOR CELLS, CULTURED;

EID: 0032254064     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Avemann, K.; Knippers, R.; Koller, T.; Sogo, J. M. Camptothecin, a specific inhibitor of type I DNA topoisomerase, induces DNA breakage at replication forks. Mol. Cell. Biol. 8:3026-3034; 1988.
2. Shin, C. G.; Snapka, R. M. Exposure to camptothecin breaks leading and lagging strand simian virus 40 DNA replication forks. Biochem. Biophys. Res. Commun. 168:135-140; 1990.
3. Tsao, Y. P.; Russo, A.; Nyamuswa, G.; Silber, R.; Liu, L. F. Interaction between replication forks and topoisomerase I-DNA cleavable complexes: Studies in a cell-free SV40 DNA replication system. Cancer Res. 53:5908-5914; 1993.
4. Holm, C.; Covey, J. M.; Kerrigan, D.; Pommier, Y. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res. 49:6365-6368; 1989.
5. Hsiang, Y. H.; Lihou, M. G.; Liu, L. F. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 49:5077-5082; 1989.
6. D'Arpa, P.; Beardmore, C.; Liu, L. F. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res. 50:6919-6924; 1990.
7. Morris, E. J.; Geller, H. M. Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase-I: Evidence for cell cycle-independent toxicity. J. Cell. Biol. 134:757-770; 1996.
8. Park, D. S.; Morris, E. J.; Greene, L. A.; Geller, H. M. G1/S cell cycle blockers and inhibitors of cyclin-dependent kinases suppress camptothecin-induced neuronal apoptosis. J. Neurosci. 17:1256-1270; 1997.
9. Palitti, F.; Cortes, F.; Bassi, L.; Di, C. D.; Fiore, M.; Pinero, J. Higher G2 sensitivity to the induction of chromosomal damage in the CHO mutant EM9 than in its parental line AA8 by camptothecin, an inhibitor of DNA topoisomerase I. Mutat. Res. 285: 281-285; 1993.
10. O'Connor, P. M.; Nieves, N. W.; Kerrigan, D.; Bertrand, R.; Goldman, J.; Kohn, K. W.; Pommier, Y. S-phase population analysis does not correlate with the cytotoxicity of camptothecin and 10,11-methylenedioxycamptothecin in human colon carcinoma HT-29 cells. Cancer Commun. 3:233-240; 1991.
11. Goldwasser, F.; Shimizu, T.; Jackman, J.; Hoki, Y.; O'Connor, P. M.; Kohn, K. W.; Pommier, Y. Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. Cancer Res. 56:4430-4437; 1996.
12. Goldwasser, F.; Bae, I.; Valenti, M.; Torres, K.; Pommier, Y. Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anti-cancer screen. Cancer Res. 55:2116-2121; 1995.
13. Hennequin, C.; Giocanti, N.; Balosso, J.; Favaudon, V. Interaction of ionizing radiation with the topoisomerase I poison camptothecin in growing V-79 and HeLa cells. Cancer Res. 54:1720-1728; 1994.
14. Barrows, L. R.; Holden, J. A.; Anderson, M.; D'Arpa, P. The CHO XRCC1 mutant, EM9, deficient in DNA ligase III activity, exhibits hypersensitivity to camptothecin independent of DNA replication. Mutat. Res. (in press).
15. Andersson, B. S.; Sadeghi, T.; Siciliano, M. J.; Legerski, R.; Murray, D. Nucleotide excision repair genes as determinants of cellular sensitivity to cyclophosphamide analogs. Cancer Chemother. Pharmacol. 38:406-416; 1996.
16. Caldecott, K. W.; Tucker, J. D.; Stanker, L. H.; Thompson, L. H. Characterization of the XRCC1-DNA ligase III complex in vitro and its absence from mutant hamster cells. Nucleic Acids Res. 23:4836-4843; 1995.
17. Caldecott, K. W.; McKeown, C. K.; Tucker, J. D.; Ljungquist, S.; Thompson, L. H. An interaction between the mammalian DNA repair protein XRCCI and DNA ligase III. Mol. Cell. Biol. 14:68-76; 1994.
18. Pourquier, P.; Pilon, A. A.; Kohlhagen, G.; Mazumder, A.; Sharma, A.; Pommier, Y. Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps. Importance of DNA end phosphorylation and camptothecin effects. J. Biol. Chem. 272:26441-26447; 1997.
19. Masson, M.; Niedergang, C.; Schreiber, V.; Muller, S.; Menissierde Murcia, J.; de Murcia, G. XRCCI is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol. Cell. Biol. 18:3563-3571; 1998.
20. Bosmann, H. B. Camptothecin inhibits macromolecular synthesis in mammalian cells but not in isolated mitochondria or E. coli. Biochem. Biophys. Res. Commun. 41:1412-1420; 1970.
21. Wu, R. S.; Kumar, A.; Warner, J. R. Ribosome formation is blocked by camptothecin, a reversible inhibitor of RNA synthesis. Proc. Natl. Acad. Sci. USA 68:3009-3014; 1971.
22. Horwitz, S. B.; Chang, C.-K.; Grollman, A. P. Studies on camptothecin: Effects on nucleic acid and protein synthesis. Mol. Pharmacol. 7:632-644; 1971.
23. Horwitz, S. B. Novel inhibitors of RNA synthesis. Fed. Proc. 33:2281-2287; 1974.
24. Zhang, H.; Wang, J. C.; Liu, L. F. Involvement of DNA topoisomerase I in transcription of human ribosomal RNA genes. Proc. Natl. Acad. Sci. USA 85:1060-1064; 1988.
25. Ljungman, M.; Hanawalt, P. C. The anti-cancer drug campto-thecin inhibits elongation but stimulates initiation of RNA polymerase II transcription. Carcinogenesis 17:31-35; 1996.
26. Bendixen, C.; Thomsen, B.; Alsner, J.; Westergaard, O. Camptothecin-stabilized topoisomerase I-DNA adducts cause premature termination of transcription. Biochemistry 29:5613-5619; 1990.
27. Wu, J.; Liu, L. F. Processing of topoisomerase I cleavable complexes into DNA damage by transcription. Nucleic Acids Res. 25:4181-4186; 1997.